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INTRODUCTION: 
Anaemia, whether clinically overt or not is a common condition 
encountered by the family physician. The most commonly encountered 
disorders manifesting with mild microcytic hypochromic anaemia are iron 
deficiency anemia (IDA) and Thalassemia Trait (TT)1,2. Hypochromic 
microcytic aneamia could also be due to anaemia of chronic disease or lead 
poisoning. The establishment of an accurate diagnosis is of great importance 
in ensuring correct treatment. Administration of iron to a patient with 
hypochromic aneamia due to a cause other than iron deficiency is not only 
useless but also leads to undesirable effects of increase in body iron stores. 
Thalassemia Minor and Thalassemia Intermedia may pass off as iron 
deficiency anaemia, if only peripheral smear was the sole diagnostic 
modality. 
β-Thalassemia is also an iron loading anemia, meaning that 
thalassemic patients have a dramatic increase in iron absorption from the gut 
due to their increased erythropoietic rate3–6. Together with the iron influx 
from chronic transfusions the setting of iron overload is observed in 
thalassemic patients. Inadvertent iron therapy will prove detrimental in such 
situations.           
Iron plays an essential role in many important biochemical processes 
7. As with all nutrients, the requirement for iron is greater during periods of 
rapid growth and differentiation such as in the late fetal and neonatal period. 
2 
 
Consequently, poor iron homeostasis during this period can result in 
disordered development. Inadequate tissue iron levels can lead to reduced 
erythropoiesis and poor O2-carrying capacity. The nervous system, which 
develops rapidly during the late fetal and early neonatal period, seems to be 
particularly susceptible to iron deficiency and excess 8. Also, Iron excess can 
have severe effects on neuron development 6–8. Thus, events occurring in 
early life can have long-lasting effects on neuronal function in the adult. 
Excessive iron in the circulation leads to abnormal accumulation in organs 
such as liver, spleen and heart, leading ultimately to liver disease, cardiac 
dysfunction, arthropathy, gonadal insufficiency and other endocrine 
disorders (Hoffman et al., Hematology, Basic Principles and Practice15). 
 
Twenty  percent of children in US and eighty percent of children in 
developing countries are anaemic at some point of time by the age of 18 
years (American fam physician 2001:64:1364-79).  Hence it is worthwhile 
to study the hematological profile including serum iron, serum iron binding 
capacity, haemoglobin electrophoresis and bone marrow iron which would 
delineate these disease entities and enable correct management. Timely 
management of anaemia in growing buds is very important especially for a 
developing country like India as the children of today are the best national 
resource of tomorrow. 
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AIM OF THE STUDY 
 
1. To find out causes of microcytic hypochromic anaemia in children & 
their respective prevalence. 
2. To study red cell indices in various types of  hypochromic microcytic 
anaemia. 
3. To analyze the Serum Iron, Total Iron Binding Capacity, Serum Ferritin 
levels in various types of hypochromic microcytic anaemia. 
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REVIEW OF LITERATURE 
DEFINITION: 
          Anaemia is defined as a reduction in the concentration of circulating 
haemoglobin or oxygen carrying capacity of blood below the level that is 
expected for healthy persons of same age and sex in the same environment.  
PREVALENCE: 
                 Anaemia remains a widespread public health problem with major 
consequences for human health as well as social and economic development. 
Although estimates of the prevalence of anaemia vary widely and accurate 
data are often lacking, it can be assumed that significant proportions of young 
children and women of childbearing age are anaemic (WHO 2001, 2003). 
Preschool children are more affected than women, with reported prevalence 
in excess of 60% in many countries. Nutritional deficiency constitutes most 
common cause of anaemia (Iron, B12, & Folic acid). 
               Genetic disorders, particularly Thalassaemia, remain another 
possibility. In a multicity study, the incidence of Thalassemia Trait has been 
found to be 2.7% in Bombay, 5.5% in Delhi & 10.4% in Calcutta (ICMR). It 
is estimated that about 10,000 children with Thalassemia Major are born 
every year in India, accounting for 10% of Thalassemia Major birth 
worldwide.  
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Thalassemia primarily affects people of Mediterranean, Southeast Asian, and 
African ancestry in malaria-endemic regions [J Nippon med Sch 2004;7112]. 
 
THE PREVALENCE AND DISTRIBUTION OF IRON 
DEFICIENCY WORLDWIDE: 
Iron deficiency is the most prevalent and the most common 
micronutrient deficiency in the developing world today (Tatala et al,199816; 
Asobayire et al.200117;Abalkhail and Shawky, 200218;Hashizume et 
al.200319). 
         The prevalence of iron deficiency varies widely depending on the 
criteria used to establish the diagnosis. Variables include age, socioeconomic 
status, family size, nutritional status and total income of the family. 
According to UNICEF report, two billion people suffer from anemia 
worldwide and most of them have iron deficiency anemia, especially in 
underdeveloped and developing countries, where 40-50% of children are iron 
deficient (UNICEF). According to world health organization (WHO), there 
are no current global figures for iron deficiency anemia, but using anemia as 
an indirect indicator 39-48% children in non industrialized countries 
compared to 6-20% in industrialized countries are iron deficient as shown in 
table (WHO, 2001). 
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Data presented in shows regions with the numbers of anemic cases in these 
regions as reported by WHO (WHO, 2001).  
Percentage of affected population 
Age group/y Industrialized Countries 
Non-industrialized 
Countries 
0-4 years 20.1 39 
5-14 years 5.9 48.1 
Females 15-59 years 10.3 42.3 
Males 15-59 years 4.3 30 
 
HEMATOPOIESIS 
EMBRYONIC HEMATOPOIESIS 
Hematopoiesis and vasculogenesis in the mammalian embryo begin in 
the blood islands of the yolk sac and continue, somewhat later, within the 
embryo proper. Blood islands are formed from mesodermal aggregates that 
have migrated from the primitive streak. The outer cells differentiate into 
endothelial cells and the inner to primitive blood cells. The close 
developmental association between hematopoietic and endothelial cell 
lineages has led to a hypothesis that they share a common progenitor, the 
hemangioblast. The mechanisms that control formation of hemangioblast and 
embryonic hematopoietic and endothelial (angioblastic) stem/progenitor cells 
are still not well understood (oxford textbook). 
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Erythropoiesis takes place within the primitive circulation 
(intravascular) and is megaloblastic in type. Multipotent progenitors derived 
from the mesoderm are present at early stages of gestation. For many years, 
investigators have believed that yolk sac blood islands contained 
Hematopoietic Stem Cells (HSC) capable of primitive hematopoiesis and of 
migration to the developing liver to initiate definitive hematopoiesis. 
Challenging the idea of a singular origin of hematopoiesis in the yolk sac, it 
has been proposed that there is a more potent intraembryonic HSC site in the 
Aorta-Gonado-Mesonephros (AGM) region. HSCs arise for the first time in 
the AGM region and migrate to the yolk sac and fetal liver, the main source 
of hematopoietic cells in fetal life. Around the time of birth, HSCs migrate 
from the liver to the bone marrow, to be responsible for adult hematopoiesis. 
          At about sixth week of gestation, erythropoiesis begins in the 
fetal liver extravascularly, with mature cells entering the fetal circulation. 
Erythropoiesis is also detectable in the spleen by the 12th week, this 
remaining the primary site of erythropoiesis untilthe 24th week. 
 
BONE MARROW HAEMATOPOIESIS: 
             This commences at around week 16 to 18, as fetal liver 
hematopoiesis is challenged by hepatocyte proliferation, and assumes the 
primary role from week 24 onward. 
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Haem is complex of protoporphyrin and iron. 
Succinyl coA + Glycine 
 
δ Amino levulinic acid 
 
 
                                    
                           Protoporphyrin IX     
                                                                             Fe 2+ 
                                                         Haem 
                                                            + 
                                                        Globin 
 
                                                    Haemoglobin 
 
GLOBIN SWITCHING: 
An orderly sequence of production of different globin proteins occurs 
during fetal development in response to changes in requirements for red 
blood cell oxygen-carrying capacity. The earliest globin chains detectable in 
the embryo yolk sac are zeta, Alpha type chain with locus on chromosome 
16, and epsilon (ε), a β-type chain with locus on chromosome 11. The earliest 
fetal haemoglobin is thus HbGower1, and it is the major form at 5 to 6 weeks. 
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HbGower 2 is present from 4 to 13 weeks of gestation. HbPortland also 
persists from 4 to 13 weeks but is found in infants with homozygous 
Thalassemia.  HbF is the major fetal form and accounts for 90 to 95% of the 
total haemoglobin until 34 to 36 weeks gestation. Adult haemoglobin (HbA) 
is detectable from week 11 of gestation, after which time the proportion of 
HbA increases as HbF declines. The amount of HbF in neonates varies from 
50 to 90%, but thereafter declines at a rate of 3% per week and is generally 
less than 2 to 3% by the age of 6 months. 
 
Relative proportions & constitutions of different haemoglobins are; 
Adults:  
 Hb A  -  α2β2  -  97% 
 Hb A2  -  α2δ2  -  2.5% 
Hb F  -  α2γ2  -  0.5 
Newborn: 
Hb F -   α2γ2   - 80%       
Hb A -   α2β2   - 20% 
Embryonic Hb: 
Hb Gower I - ζ2ε2 
 Hb Gower II - α2ε2 
Hb Portland - ε2γ2 
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FETAL BLOOD CELL VALUES 
Haemoglobin concentration rises from a mean of 11.7 g/dl at 18 weeks 
to 13.6 g/dl at >30 weeks, with a steady rise in hematocrit (0.37 l/l to 0.43 l/l) 
and concomitant fall in mean cell volume (131 fl to 114 fl). Circulating 
normoblasts constitute 45% of nucleated cells at 18 weeks, falling to 17% at 
>30 weeks. Lymphocyte percentage falls from 88% to 68%, with neutrophils 
only rising significantly after 30 weeks (8% at 26 to 29 weeks to 23% at >30 
weeks). Eosinophil, monocyte, and basophil percentages remain reasonably 
constant throughout. Platelet concentration also remains constant. (Oxford 
Handbook). 
MEASUREMENT OF ERYTHROPOIESIS 
Normal red blood cell production is extremely effective, and most red 
blood cells live, or have the potential to live, a normal life span. Under 
certain conditions, however, a fraction of red blood cell production is 
ineffective, with destruction of nonviable red blood cells either within the 
marrow or shortly after the cells reaches the blood.  
EFFECTIVE ERYTHROPOIESIS 
        It is most simply estimated by determining the reticulocyte count. This 
count is usually expressed as the percentage of red blood cells that are 
reticulocytes, but it can also be expressed as the total number of circulating 
reticulocytes per liter of blood (reticulocyte % × RBC per l). An elevated 
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reticulocyte count may give an erroneous impression of the actual rate of red 
cell production because of premature release of reticulocytes into the 
circulation. 
 
 INEFFECTIVE RED BLOOD CELL PRODUCTION: 
        Ineffective erythropoiesis is suspected when the reticulocyte count is 
low or is normal or only slightly increased in the presence of erythroid 
hyperplasia in the bone marrow. In certain disorders, such as Addisonian 
pernicious anemia, Thalassemia, and sideroblastic anemia, ineffective 
erythropoiesis is a major component of total erythropoiesis. This can be 
quantified by ferrokinetics. Using ferrokinetic methods, ineffective 
erythropoiesis is calculated as the difference between total plasma iron 
turnover and erythrocyte iron turnover plus storage iron turnover. 
 
HEMATOPOIETIC REGULATION 
The maintenance of hematopoiesis in steady state by a balance of 
negative and positive cytokine regulators. A variety of the cytokines that 
include the Hematopoietic Growth Factors (HGFs), Stem Cell Factor (SCF), 
flt3 ligand (FL), Thrombopoietin (TPO), Interleukin-3 (IL-3), Granulocyte/ 
Macrophage Colony Stimulating Factor (GMCSF), and IL-6 have been 
shown, in various combinations, to promote the growth and differentiation of 
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Hematopoietic Stem Cells (HSCs). HSC proliferation is intimately linked to 
the stromal cells and Extra Cellular Matrix (ECM) in distinct 
microenvironmental niches.  They composed of a variety of molecules, 
including fibronectin, laminin, collagens, and proteoglycans. Some 
components of the ECM bind to cytokines produced by the stroma, 
immobilizing them within the microenvironmental niches and thus creating a 
zone in which HSCs and cytokines can coalesce.  
 
IRON METABOLISM 
Most of the iron is present in the oxygen carrying protein of the red 
blood cells-haemoglobin. Iron turnover is also dominated by the synthesis 
and breakdown of haemoglobin. Haem is synthesized in nucleated red cells in 
the bone marrow by a pathway ending with the incorporation of iron into 
protoporphyrin IX by ferrochelatase. Haem breakdown takes place in 
phagocytic cells, largely those in the spleen, liver and bone marrow. Iron is 
released from haem by haem oxygenase and is largely reused for haem 
synthesis. Every day about 30 mg of iron are used to make new haemoglobin 
and most of this obtained from the breakdown of old red cells.  
            Relatively little iron is lost from the body (about 1mg/day in men) and 
these losses are not influenced by body iron content or the requirement of the 
body iron. The body iron content is maintained by variation in amount of iron 
absorbed. In most men and postmenopausal women there is some storage 
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iron. This is iron in ferritin or its insoluble derivative haemosiderin which is 
available for haem synthesis if necessary. 
 
DIETARY IRON ABSORPTION 
Iron absorbed depends on 13  
• The amount of iron in the diet 
• Its bioavailability 
• The body’s need for iron 
• Age and  
• Inflammatory states with hepcidin release 
Nonhaem iron is released from food as Fe 3+ and reduced to Fe2+ by a 
membrane – bound ferrireductase, Dcytb. 
                Iron is transported across brush-border membrane by the metal 
transporter, DMT-1. Some iron is incorporated into ferritin and lost when the 
cells are exfoliated. 
                Iron destined for retention by the body transported across the 
serosal membrane by ferroportin-1. Before uptake by transferrin, Fe2+ is 
oxidised to Fe3+ by hephaestin or by plasma ceruloplasmin.  
            Haemoglobin and myoglobin are digested in the stomach and small 
intestine. Haem is initially bound by haem receptors at the brush border 
membrane and the iron is released intracellularly by haem oxygenase before 
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entering the labile iron pool and following a common pathway with iron of 
nonhaem origin14. 
 
REGULATION OF IRON ABSORPTION  
 Iron absorption may be regulated both at the stage of mucosal 
uptake and at the stage of transfer to the blood. As epithelial cells develop in 
the crypts of Lieberkuhn their iron status reflects that of plasma (transferrin 
saturation) and this programmes the cells to absorb iron appropriately as they 
differentiate along the villus. 
           Transfer to the plasma depends on the requirements of the erythron for 
iron and the level of iron stores. This regulation is mediated directly by 
hepcidin, a peptide synthesized in the liver in response to iron and 
inflammation. Hepcidin blocks intestinal iron absorption and iron release 
from liver and spleen. The main mechanism by which hepcidin exerts its 
effects appears to be control of ferroportin. Indeed, ferroportin is the only 
known cellular iron exporter which cannot mediate iron release from the cell 
once hepcidin exerts its actions. 
 
CELLULAR IRON UPTAKE AND RELEASE 
 Transferrin binds to the transferrin receptor (TfR) lining the cell. 
The two proteins bind strongly to form a high affinity complex which 
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initiates endocytosis of the local membrane. The resulting endosome contains 
the transferrin-transferrin receptor complex. The pH of the endosome is then 
reduced by a proton pump to induce a conformational change in 
holotransferrin, which releases its iron. Iron is transported into the cell via 
DMT-1. This iron is then either stored as ferritin or used within the cell (for 
Hb synthesis in erythroid precursors). The apotransferrin and transferrin 
receptor return to the cell surface where they dissociate at neutral pH so that 
the cycle can start again. 
 The reticuloendothelial macrophages play a major role in recycling 
iron resulting from the degradation of haemoglobin from senescent 
erythrocytes. They engulf red blood cells and release the iron within using 
haem oxygenase. The iron is rapidly released to plasma transferrin or stored 
as ferritin. Little is known about the mechanism of release, but ferroportin 1 
may be as essential component. 
 Ferritin is found in all the cells and in the highest concentration in 
liver, spleen and bore marrow14. 
 With the recognition that the small quantity of ferritin in human 
serum (15-300 µg/L in healthy men) reflects body iron stores, measurement 
of serum ferritin has been widely adopted as a test for iron deficiency and 
iron overload. 
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IRON NEEDS DURING INFANCY AND CHILDHOOD  
 To meet the needs of iron for growth and to replace normal losses, 
iron intake must supplement the approximately 75 mg of iron per kilogram of 
body weight that is present at birth (Widdowson, Spray, et al.21). Iron losses 
from the body are small and relatively constant. About two thirds of iron 
losses in infancy occur when cells are extruded from the intestinal mucosa 
and the remainder when cells are shed from the skin and urinary tract. In the 
normal infant, these losses average approximately 20 mg per kilogram per 
day. An infant who weighs 3kg at birth and 10kg at one year of age will 
require approximately 270 to 280mg of additional iron during the first year of 
life to maintain normal iron stores [Widdowson et al.21]. 
          Breast milk and cow's milk both contain about 0.5 to 1.0mg of iron per 
liter, but its bioavailability differs markedly. The absorption of iron from 
breast milk is uniquely high, about 50 percent on an average and tends to 
compensate for its low concentration (Bioavailability). In contrast, only about 
10% of the iron in whole cow's milk is absorbed. About 4% of iron is 
absorbed from iron fortified cow's-milk formulas that contain 12mg of iron 
per liter (Saarinene et al.22, McMillan et al.). The reasons for the high 
bioavailability of iron in breast milk are unknown, although it appears that 
the high concentrations of calcium, phosphorus, and protein, in conjunction 
with the low concentration of ascorbic acid, are responsible, in part, for the 
poor absorption of iron from cow's milk. 
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             After one year of age, the diet becomes more varied and there is less 
information from studies on which to base dietary recommendations. The 
recommended dietary allowance decreases to 10mg per day for children 
between 4 and 10 years of age and then increases to 18mg per day at the age 
of 11 to provide for the accelerated growth that take place during adolescence 
(Elk et al.23). Two thirds of body iron is present in circulating red blood cells 
as haemoglobin. Each gram of haemoglobin contains 3.47 mg of iron; thus, 
each ml of blood lost from the body (haemoglobin 15 g/dl) results in a loss of 
0.5 mg of iron (Conrad et al.). 
        Hookworms also reported as other causative bleeding agents as 35% of 
ID total reported to suffer from hookworm infections. Necator americanus or 
Ancylostoma duodenale are the most common parasitic species involved in 
bleeding; however, further investigation is required for the identification of 
such parasites (Hopkins et al.25). 
 
IRON DIFICIENCY ANAEMIA 
Iron balance is usually achieved by regulation of iron absorption in the 
proximal small intestine. Either diminished absorbable dietary iron or 
excessive loss of body iron can cause iron deficiency. 
               Diminished absorption is usually due to an insufficient intake of 
dietary iron in the absorbable form. While body loss of iron quantitatively is 
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as important as absorption in terms of maintaining iron equilibrium, it is a 
more passive process than absorption. Consistent errors in maintaining this 
equilibrium lead to either iron deficiency or iron overload (Conrad et al. ). 
Also some constituents present in the food regulate the absorption of Iron. 
Ascorbic acid enhances the absorption of non-heme iron, as do meat, fish, 
and poultry (Derman et al.26). Inhibitors of absorption include bran, 
polyphenols, oxalates, phytates, vegetable fiber, the tannins in tea, and 
phosphates (Charlton and Bothwell et al.27).  
 Iron-deficiency anemia can be the consequence of several factors, including: 
• Insufficient iron in the diet 
• Poor absorption of iron by the body 
• Ongoing blood loss, most commonly from menstruation or from 
gradual blood loss in the intestinal tract 
• Periods of rapid growth 
• Damage of intestines 
• Infection and disturbance of mucosa 
• Elevation of pancreatic secretions 
Children between 1 and 3 years of age are at risk of iron deficiency and 
iron-deficiency anemia, even though it is not a period of exceptional growth. 
Most toddlers are no longer consuming iron-fortified formula and infant 
cereal, and they are not eating enough iron-rich foods to make up for the 
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difference. Toddlers also tend to drink a lot of cow's milk, often more than 24 
ounces a day. During the first stages of puberty, when growth spurt occurs, 
boys are at risk of iron-deficiency anemia. Adolescent girls are at higher risk 
because of menstrual blood loss and smaller iron stores when compared to 
boys (Christopher et al.28). 
 
SYMPTOMS OF IRON DEFICIENCY ANEMIA 
Many people with iron deficiency anemia will not suffer from 
additional symptoms; however several common symptoms of iron deficiency 
anemia are well defined.  
The symptoms include: 
• Headache, 
• Abnormal pallor or lack of color of the skin, 
• Irritability, 
• Lack of energy or tiring easily (fatigue), 
• Increased heart rate (tachycardia), 
• Sore or swollen tongue, 
• Enlarged spleen, 
• A desire to eat peculiar substances such as dirt or ice in large amounts. 
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DIAGNOSIS OF IRON DEFICIENCY ANEMIA 
Iron-deficiency anemia develops as an end result of a series of steps that 
begin with depletion of stored iron. First, iron disappears from the bone 
marrow, and the red-cell distribution width becomes abnormal. Next, there is 
a loss of transport iron, reflected by a reduced serum iron level. Then, 
erythropoiesis becomes iron-deficient, as indicated by a reduced mean 
corpuscular volume and an increased concentration of red-cell 
protoporphyrin. The result is overt anemia. 
    Diagnosis of moderate or severe iron-deficiency anemia is easy. The 
disease is characterized by low MCV, reduced serum ferritin level, reduced 
serum iron level, increased serum iron-binding capacity, increased red-cell 
protoporphyrin level, and increased red-cell distribution width. The diagnosis 
of mild forms of iron-deficiency anemia may present a greater challenge. The 
laboratory tests may be less reliable, and the values of iron deficient and iron-
sufficient persons overlap considerably (Charlton et al., Yip et al.27). The 
following represent general considerations: 
• A complete blood count (CBC) may reveal low haemoglobin levels 
and low hematocrit (the percentage of red blood cells in whole blood).  
• The CBC also gives information about the size of the red blood cells 
(RBCs). RBCs with low haemoglobin tend to be smaller and less 
pigmented (Microcytic and hypochromic). 
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• Serum iron directly measures the amount of iron in blood, but may not 
accurately reflect iron concentrations in cells. 
• Serum ferritin reflects total body iron stores. It is one of the earliest 
indicators of depleted iron levels, especially when used in conjunction 
with other tests, such as (CBC). 
The most useful single laboratory value for the diagnosis of iron 
deficiency may be plasma ferritin. Ferritin is the cellular storage protein for 
iron. Plasma ferritin differs from its cellular counterpart in several respects, 
and appears to be a secreted protein of different origin (Arosio et al.29). 
Plasma ferritin values often falls under 10% of its baseline levels with 
significant iron deficiency. 
 
ANAEMIA OF CHRONIC DISEASE 
PATHOPHYSIOLOGY 
         Anaemia of chronic disease is of immunological origin. In clinical 
setting, it is mostly found in the patients with chronic inflammatory process, 
chronic infectious disease and in patients with malignant tumors. 
Perturbations in iron homeostasis can be found that are associated with an 
increased uptake and retention of iron in the cells of the reticuloendothelial 
system. This leads to the deposition of iron in the cells of the 
reticuloendothelial system, which, in turn yields a lack of iron for 
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erythropoiesis. The increase in iron storage appears to be mediated by pro-
inflammatory cytokines. 
            Tumor necrosis factor-alpha, for example, inhibits synthesis of the 
iron storage protein ferritin in macrophages and hepatocytes. Additionally, 
the expression of the membrane protein DMT1 is upregulated by interferon-
gamma, bacterial lipopolysaccharide and tumor necrosis factor-alpha. This 
protein mediates iron transport into the intestinal mucosal cell as well as into 
activated macrophages. Moreover, export of iron from these cells is inhibited 
through down regulation of the expression of ferroportin.  
 
             Hepcidin appears to play a central role in this setting, because it is 
more abundantly expressed under the influence of lipopolysaccharide and 
interleukin-6 secretion. This, in turn, yields an additional inhibition of iron 
absorption from the gut. Furthermore, the action of aforementioned 
cytokines, especially that of interferon-gamma, leads to a direct suppression 
of erythropoiesis. It has been proposed that the responsible mechanisms are 
an induction of apoptosis and inhibition of erythropoietin expression. 
 
        In addition to the effects of iron sequestration, inflammatory cytokines 
promote the production of white blood cells. Bone marrow produces both red 
blood cells and white blood cells from the same precursor stem cells. 
Therefore, the upregulation of white blood cells causes fewer stem cells to 
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differentiate into red blood cells. This effect may be an important additional 
cause for the decreased erythropoiesis seen in anaemia of inflammation, even 
when erythropoietin levels are normal, and even aside from the effects of 
hepcidin.       
             In the short term, the overall effect of these changes is likely positive: 
it allows the body to keep more iron away from bacterial pathogens in the 
body, while producing more immune cells to fight of infection. Bacteria, like 
most living forms, depend on iron to live and multiply. However, if 
inflammation continues, the effect of locking up iron stores is to reduce the 
ability of the bone marrow to produce red blood cells. 
 
CLINICAL PROFILE 
         The anaemia of chronic disease presents itself as a normochromic 
normocytic anaemia14. It normally does not lead to a decrease in haemoglobin 
below 8 g/dl. The diagnosis is usually established by a low serum iron 
concentration, a low transferrin concentration, a low transferrin saturation, and 
normal or increased ferritin values in the presence of chronic illness30,31. The 
number of reticulocytes is usually low, which points to a small rate in de novo 
production. Serum values of iron and transferrin saturation are normally 
reduced, because the iron is trapped inside the rediculoendothelial system32. 
Assessing C-reactive protein values is usually helpful to differentiate acute 
inflammatory process31. 
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β-THALASSEMIA 
PATHOPHYSIOLOGY OF β-THALASSEMIA: 
Thalassaemia is inherited as an autosomal recessive disorder 
characterized by a microcytic hypochromic anaemia, and a clinical phenotype 
varying from almost asymptomatic to a lethal haemolytic anaemia. It is 
characterized by decreased or absent globin chain synthesis and by 
ineffective erythropoiesis. It is classified according to the defective globin 
chain and clinical severity. 
Individuals who are homozygotes for β-Thalassemia genes (β+/β+, 
β0/β0) have a severe, transfusion dependent anaemia called β-Thalassemia 
Major. Heterozygotes with one Thalassemia gene and one normal gene (β+/β 
or β0/β) usually have a mild microcytic anaemia that causes no symptoms. 
This condition is known as Thalassemia Minor or Thalassemia Trait. 
Thalassemia Intermedia are is the third genetic variant of the β-
Thalassemias,(β+/β+ or β0/ β)  which incorporates a less severe anemia than 
Thalassemia Major with inefficient erythropoiesis as well as peripheral 
hemolysis. 
Three main sequelae which are responsible for the clinical 
manifestation of Thalassemia Intermedia are ineffective erythropoiesis, 
chronic anemia, and iron overload. Ineffective erythropoiesis is due to 
imbalance between the β, α chain synthesis. Free α chains precipitate within 
the normoblast, forming insoluble inclusions. These inclusions cause cell 
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membrane damage, and premature destruction within the bone marrow 
leading to ineffective erythropoiesis, and also lysis of premature red cells in 
the spleen (hemolysis). 
Leg ulcers, pulmonary arterial hypertension, extramedullary 
hematopoiesis, and thrombotic events are some of the complications that 
Thalassemia Intermedia patients. Thalassemia Intermedia encompasses a 
wide clinical spectrum. Mildly affected patients are completely asymptomatic 
until adult life, experiencing only mild anemia and maintaining haemoglobin 
levels between 7 to 10 g/dl. These patients require only occasional blood 
transfusions, if any. Patients with more severe Thalassemia Intermedia 
generally present between the ages of 2 and 6 years, and although survival 
does not depend on regular transfusion therapy, growth and development can 
be retarded. Thalassemia Minor is more common than Thalassemia Major 
(Robbins). These patients are usually asymptomatic; anaemia is mild.  
Recognition of β Thalassemia Trait is important on two accounts: 
1. Differentiation of microcytic hypochromic anaemia from Iron 
deficiency anaemia. 
2. Genetic counseling. 
Even though prevalence of anaemia is less common in Japan, a study 
conducted in junior high school children, two children with hypochromic 
microcytic anaemia were found to be diagnosed as Thalassemia Intermedia.  
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[J Niipon Med Sch 2004: 7112]. This shows the importance of screening for 
hypochromic microcytic anaemia. 
Differentiation can be reasonably made between Iron deficiency 
anaemia and β Thalassemia Trait using Red cell counts. Elevated Red cell 
count especially in the presence of mild anaemia was a reliable indicator of β 
Thalassemia Trait.(Nishi madhan et al.) in this study 287 Trait had an 
elevated RBC count in contrast to 9 in Iron deficient subjects. 
DIAGNOSIS 
CLINICAL DIAGNOSIS 
Thalassemia Major is usually suspected in an infant younger than two 
years of age with severe microcytic anemia, mild jaundice and 
hepatosplenomegaly. Thalassemia Intermedia presents at a later age with 
similar but milder clinical findings. Carriers are usually asymptomatic, but 
sometimes may have mild anemia. Hematologic Diagnosis RBC indices 
show microcytic anemia. Thalassemia Major is characterized by reduced Hb 
level (<7 g/dl), mean corpuscular volume (MCV) > 50 < 70 fl and mean 
corpuscular Hb (MCH) > 12< 20 pg. 
          Thalassemia Intermedia is characterized by Hb level between 7 and 10 
g/dl, MCV between 50 and 80 fl and MCH between 16 and 24 pg. 
Thalassemia Minor is characterized by reduced MCV and MCH, with 
increased Hb A2 level35. 
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PERIPHERAL BLOOD SMEAR 
• Affected individuals show RBC morphologic changes [microcytosis, 
hypochromia, anisocytosis, poikilocytosis (speculated tear-drop and 
elongated cells), and nucleated RBC (i.e., erythroblasts). The number 
of erythroblasts is related to the degree of anemia and is markedly 
increased after splenectomy. 
• Carriers have less severe RBC morphologic changes than affected 
individuals. Erythroblasts are normally not seen. Qualitative and 
quantitative Hb analysis (by cellulose acetate electrophoresis and DE-
52 microchromatography or HPLC) identifies the amount and type of 
Hb present. The Hb pattern in β-Thalassemia varies according to β-
Thalassemia type. In beta0 Thalassemia, homozygotes HbA is absent 
and HbF constitutes the 92-95% of the total Hb. In beta+ Thalassemia 
homozygotes and beta+/beta0 genetic compounds HbA levels are 
between 10 and 30% and HbF between 70-90%. HbA2 is variable in 
β-Thalassemia homozygotes and it is enhanced in beta Thalassemia 
Minor. 
MOLECULAR GENETIC ANALYSIS 
• The prevalence of a limited number of mutations in each population 
has greatly facilitated molecular genetic testing. Commonly occurring 
mutations of the beta globin gene are detected by PCR-based 
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procedures [36]. The most commonly used methods are reverse dot blot 
analysis or primer-specific amplification, with a set of probes or 
primers complementary to the most common mutations in the 
population from which the affected individual originated. 
• If targeted mutation analysis fails to detect the mutation, beta globin 
gene sequence analysis can be used to detect mutations in the beta 
globin gene. 
Table-4; Serum values in various hematological profiles of 
microcytic hypochromic anaemia: 
Parameter  Iron deficiency 
Anaemia 
β- 
Thalassemia 
Anaemia of chronic 
Desease 
Iron ↓ ↑ ↓ 
Transferrin Saturation ↓ ↑ ↑ 
Ferritin ↓ ↑ ↑ 
S. transferrin Receptor ↑ ↔ Normal 
Ratio of S. transferrin 
receptor to log ferritin 
High ( >2) Low ( <1) ↓ 
Cytokines level ↔ ↑ ↑ 
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RED CELL INICES AND FUNCTIONS: 
 Several studies have derived discriminatory functions based on 
RBC indices that can be used to differentiate between patients with 
Thalassemia and those with Iron deficiency anaemia (Shine and lal et al.39).     
Red cell indices used to are; 
• Mentzer index (MI) 
• Shine and lal index (S&L) 
• England and Fraser index (E &F) 
• Srivastava index (S) 
• Green and King index (G&K) 
• RDW index (RDWI) 
• Ricerca index (R) 
 
A study conducted by V Okan, A Cigilogu, S cifci et al47, calculated the 
sensitivity, specificity, Positive predictive value, Negative predictive value of 
these nine indices. The study included 100 β Thalassemia Trait cases and 100 
Iron deficiency anaemia in the age group range of 15- 87 years.  They found 
that Shine and Lal and Green & King indices to be the best at differentiating 
Iron deficiency anaemia from Thalassemia patients and RDW index to be the 
worst.  
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       These indices have been proposed during the past 35 years to 
discriminate between the two ( Sirdah et al.42). An ideal discrimination index 
should have high sensitivity and specificity and is easy to calculate. (M.A. 
Ehsani et al.53) 
 
PERIPHERAL SMEAR EXAMINATION: 
MICROCYTES: 
 Microcytes usually result from defect in haemoglobin synthesis. It 
should be distinguished from red cell fragmentation. Both abnormalities can 
lead to a reduction in the mean cell volume. However low MCV is common 
in association with a defect in Haemoglobin synthesis, where as it is 
uncommon in fragmentation syndromes because the fragments usually 
comprise only a small percentage of erythrocytes. 
HYPOCHROMASIA: 
            Normal central pallor will be increased due to defective haemoglobin 
synthesis. 
BASOPHILIC STIPPLING:   
            It denotes the presence of numerous basophilic granules distributed 
throughout the cell. Basophilic stippling is indicative of disturbed rather than 
increased erythropoiesis. It occurs in conditions other than Thalassemia, 
which includes megaloblastic anaemia, infections, liver disease and lead 
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poisoning (Dacie and Lewis).  Coarse basophilic stippling is defined as 
easily identified, uniformly distributed basophilic inclusions. 
 
PREKERATOCYTES:  
They are RBCs with 1 or more sharp-edged, submembranous vacuoles and 
central pallor. They are commonly observed in Iron deficiency anaemia 
(Alexandara et al).  
 
PENCIL CELLS: 
      They are elongated, hypochromic RBCs, in which the long axis was 
more than 3 times the length of the short axis, more commonly seen in IDA 
compared to Beta TT. 
 
TARGET CELLS: 
         They are RBCs with a central haemoglobinized area surrounded by an 
area of pallor. They are more commonly observed in Beta TT compared to 
IDA. 
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MATERIAL AND METHODS 
 STUDY DESIGN:- 
Prospective study 
 STUDY POPULATION:- 
        Patients aged 1-12 years with microcytic hypochromic anaemia. 
 SAMPLE SIZE:- 
A total of forty patients with hypochromic microcytic anaemia were 
subjected to assessment of hematological profile. Approximately 1200 
samples of hypochromic microcytic anaemia are received in the department 
of pathology per year representing 3.67% of incidence. 
 STUDY PERIOD:- 
One and a half years [February 2009 to August 2010]. 
 METHODOLOGY:- 
Patients aged 1-12 years with microcytic hypochromic anaemia are 
selected with following inclusion and exclusion criteria. 
 INCLUSION CRITERIA:- 
• Age group 1-12 years. 
• Patients with clinical symptoms of anaemia. 
• Haemoglobin level:  Age 1-6 years <10.5 g/dl, 7-12 years <11 g/dl. 
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II. EXCLUSION CRITERIA:- 
• Age below one year and above twelve years. 
• Peripheral smear with dimorphic picture. 
• H/O transfusion within past two months. 
• Children on haematinics. 
 
 REFERENCE VALUE (dacie and lewis): 
Indices 1 year 2- 6 years 6- 12 years 
Red cell count x1012/l 4.5(+/-)0.6 4.6 (+/-)0.6 4.6(+/-)0.6 
Haemoglobin g/l 126(+/-)15 125(+/-)15 135(+/-)20 
PCV l/l 0.34(+/-)0.04 0.37(+/-)0.03 0.40(+/-)0.05 
MCV fl 78(+/-)6 81(+/-)6 86(+/-)9 
MCH pg 27(+/-)2 27(+/-)3 29(+/-)4 
MCHC g/l 340(+/-)20 340(+/-)30 340(+/-)30 
Reticulocyte x109/l 30-100 30-100 30-100 
 
[PCV- Packed Cell Volume, MCV- Mean Cell Volume, MCH- Mean Cell 
Hb, MCHC – Mean Cell Hb Concentration].  
Complete hemogram was done using sysmex KX-21, semi automated 
haematology analyzer (Manufacturer: Sysmex corporation, Japan).  
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 DETECTION PRINCIPLE: 
         This instrument performs blood cell count by DC detection method. 
Blood sample is aspirated, measured to a predetermined volume, diluted at 
the specified ratio, and then fed into the each transducer. The transducer 
chamber has a minute hole called aperture. On both sides of the aperture there 
are electrodes between which flows the direct current. Blood cells suspended 
in the diluted sample pass through the aperture, causing direct current 
resistance to change between the electrodes. As the current resistance 
changes, the blood cell size is detected as electric pulses. Blood cell count is 
calculated by counting the pulses, and a histogram of blood cell size is plotted 
by determining the pulse size. Also analyzing a histogram makes it possible 
to obtain various analysis data. 
To analyze the haemoglobin by automated methods, the 
cyanmethaemoglobin or oxyhaemoglobin methods have so far been the 
mainstream. 
Serum Iron level assay: 
        Method:  Ferrozine method without deproteinization. 
Serum Iron binding capacity: 
       Method:   Spectrophotometric assay. 
Ferritin estimation:  
       Method: Fully automated biodirectionally interfected chemiluminescent 
immuno assay. 
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PRINCIPLE OF IRON & TIBC ESTIMATION: 
Iron bound to transferrin, is released in an acidic medium and the ferric 
ions are reduced to ferrous ions, the Fe(II) ions react with ferrozine to form a 
violet coloured complex. Intensity of the complex formed is directly 
proportional to the amount of Iron present in the sample. 
 
For TIBC, the serum is treated with excess of Fe(II) to saturate the Iron 
binding sites on transferrin. The excess Fe(II) is adsorbed and precipitated 
and the Iron content in the supernatant is measured by spectrophotometry to 
give the TIBC.            
        Acidic medium 
                                     Fe(III)                               Fe(II) 
                  Fe(II)   + Ferrozine                              violet coloured complex 
 
RED CELL INDICES: 
1. Mean corpuscular volume (MCV) in femtolitres 
                   Packed cell volume in % 
MCV =                                                         x 10 
                Red cell count in millions/cmm 
 
2. Mean corpuscular haemoglobin (MCH) in picograms 
                   Haemoglobin (gm/dl) 
MCH =                                                        x 10 
                Red cell count in millions/cmm 
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3. Mean corpuscular haemoglobin concentration (MCHC) in gm/dl 
                    Haemoglobin (gm/dl) 
MCHC =                                             x 100 
                   Packed Cell Volume (%) 
 
       4. Reticulocyte count: 
                                      Reticulocyte counted 
Reticulocyte count =                                              x 100 
                                       Number of red cells 
 
Following indices were also obtained for these patients 
          Red Blood Cell (RBC) count 
RBC Distribution Width (RDW)  
                                   Mean cell volume 
           Mentzer index            =      
                                Red blood cell count 
 
Shine and Lal Index = Mean cell volume 2 X Mean corpuscular                              
 Haemoglobin X 0.01 
 
         England & Fraser Index =Mean cell volume-Red blood cell-5Hb-3Hb 
 
                                 Mean corpuscular Hb 
Srivasthava index     =     
                                    Red blood cell 
  
  Green & king index   = Mean cell volume2 X RDW 
                                        100 Hb                                       
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                Mean cell volume X RDW 
         RBC Distribution width index =  
                                                                RBC 
 
                         Red cell distribution width 
Ricerca index     =   
                            Red blood cell count             
 
Threshold values of Indices used to discriminate between Iron deficiency 
anaemia and β–Thalassemia Trait 
Indices IDA β  - TT 
Ricerca Index >4.4 <4.4 
RBC count                     <5 >5 
RBC distribution width >14 <14 
Mentzer index >13 <13 
Shine and Lal index >1530 >1530 
England and Fraser  Index Positive Negative 
Srivastava Index >3.8 <3.8 
Green and King Index >65 <65 
RBC distribution width index >220 <220 
 
RED CELL DISTRIBUTION WIDTH: 
This is an quantitative measurement of variation in cell volume, that  is 
percentage of cells falling above and below Mean cell volume.  Actually it is 
microscopic equivalent to degree of anisocytosis. RDW is derived from the 
pulse height analysis and can be expressed as standard deviation (in fl) or as 
coefficient of variation (cv%). Reference value:  SD: 42. 5 (+/_) 3.5 fl. 
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OBSERVATION AND RESULTS 
Newly diagnosed cases of microcytic hypochromic anaemia admitted to 
Coimbatore Medical College hospital with no prior blood transfusion or iron 
treatment were randomly enrolled. A total of 44 cases were enrolled as per 
inclusion and exclusion criteria. 
AGE: 
Patient with Microcytic Hypochromic Anaemia with age between 1-12 years 
were included in this study. Out of 44 cases, 27.3% were below 4 years, 
36.4% were between 5-8 years & 36.4% were between 8-12 years. 
Table-1: Age incidence 
Age 
(in years) 
Study 
population Percent 
1-4  12 27.3 
5-8  16 36.4 
9-12  16 36.4 
Total 44 100.0 
                                              [n=Total number of cases (44)] 
 
SEX 
Among the randomly enrolled 44 patients, 25 were girls while the remaining 
19 were boys. Girls constituted 56.82%, boys constituted 43.18%. 
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SEVERITY OF ANAEMIA  
Mild anaemia (Hb 10-12 g/dl) was present in 26 cases, moderate anaemia 
(Hb 8-9.9 g/dl) in 13 cases and severe anaemia (Hb <8 g/dl) in 5 cases. 
                                 Table-2: Severity of anaemia: 
 Hb (g/dl) Study population Percent 
< 8 26 59.1 
8 – 9.9 13 29.5 
10 – 11 5 11.4 
Total 44 100.0 
 
 
MEAN CORPUSCULAR VOLUME (MCV) 
97.7% of study population had MCV below 80 fl.  
Table-3: MCV distribution 
MCV(fl) Study population Percent  
<80 43 97.7 
80 – 100 1 2.3 
Total 44 100.0 
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MEAN CORPUSCULAR HAEMOGLOBIN 
93.2% had MCH below 25pg.  
Table-4: MCH distribution 
 MCH (pg) Study population Percent  
   25 & below 41 93.2 
26 – 34 3 6.8 
Total 44 100.0 
 
 
 
MEAN CORPUSCULAR HAEMOGLOBIN CONCENTRATION  
95.5% had MCHC below 30 g/dl. 
Table-5: MCHC distribution 
MCHC (g/dl) Study population Percent  
30 & below 42 95.5 
31 – 37 2 4.5 
Total 44 100.0 
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SERUM FERRITIN: 
Out of 44 cases, 52.3% had S. Ferritin below 12ng/dl, 20.5 % had S. Ferritin 
between 12-50ng/dl & 27.3% had S. Ferritin above 50ng/dl. 
Table-6: Serum Ferritin 
S. Ferritin 
(ng/dl) 
Study 
population Percent 
<12 23 52.3 
12-50 9 20.5 
>50 12 27.3 
Total 44 100.0 
 
TOTAL IRON BINDING CAPACITY: 
Out of 44 cases, 6.8% had TIBC < 250 µg/dl, 45.5% had TIBC between 
250-400 µg/dl & 47.7% had TIBC >400 µg/dl.  
Table-7: Total Iron binding capacity (TIBC) 
TIBC (µg/dl) Study population Percent 
<250 3 6.8 
250-400 20 45.5 
>400 21 47.7 
Total 44 100.0 
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SERUM IRON IN FEMALE CHILDREN: 
Out of 25 girls in the study population, 80% had S. Iron < 60 µg/dl, 4% had 
S. Iron 60- 160 µg/dl & 16% had S. Iron >160 µg/dl.                  
                              Table-8: Serum Iron in girls  
S. Iron 
(µg/dl) 
No. of girls in 
the study  Percent 
<50 20 80.0 
50-150 1 4.0 
>150 4 16.0 
Total 25 100.0 
                                    
SERUM IRON IN MALE CHILDREN:  
89. 5% of boys in the study population had a S. Iron below 35µg/dl. 
Table-9: Serum Iron in boys  
S. Iron (µg/dl)  No. of boys in the study Percent 
<50 18 94.7 
50-150 - - 
>150 1 5.3 
Total 19 100.0 
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AGE WISE STATISTICAL ANALYSIS 
Mean haemoglobin level does not vary significantly with age. When 
ANOVA test was conducted (F=2.765; P>0.05) the mean haemoglobin was 
highest in the age group of 9- 12 years (7.76 g/dl) and lowest in the age 
group of 1-4 years (5.93 g/dl). 
Table-10:  Haemoglobin in various age groups 
Age       
(in years) 
Haemoglobin (g/dl) 
Mean S.D 
Study 
population 
1 – 4 5.93 2.08 12 
5 – 8 6.33 2.13 16 
9 – 12 7.76 2.39 16 
Total 6.74 2.31 44 
 
RBC COUNT IN VARIOUS AGE GROUPS 
 Mean RBC counts varied significantly with age. When ANOVA test was 
conducted (F=  4.799; P<0.05*) the mean RBC count was highest in the age 
group of  9- 12 years (3.81million/ mm3) and lowest in the age group of  5-8 
years (2.73 million/mm3).                              (*- significant at 5% level) 
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                       Table-11: RBC count in various age groups 
Age  
(in years) 
RBC count 
(million/mm3) 
Mean 
S.D  Study population 
1-4 2.82 0.81 12 
5-8 2.73 0.96 16 
9-12 3.81 1.31 16 
Total 3.15 1.16 44 
                                                        [SD= Standard deviation] 
 
HAEMATOCRIT IN VARIOUS AGE GROUPS 
Mean haematocrit does not vary significantly based on age. When ANOVA 
test was  conducted (F=  3.098 ; P>0.05) the mean haematocrit was highest 
in the age group of  9- 12 years ( 22.33%) and lowest in the age group of  5-
8 years (17.10%). 
                  Table-12: Haematocrit (HCT) in various age groups 
Age  
(in years) 
HCT (%) 
Mean S.D 
Study 
population 
1 – 4 17.59 6.96 12 
5 – 8 17.1 6.3 16 
9 – 12 22.33 6.2 16 
Total 19.13 6.76 44 
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MEAN CORPUSCULAR VOLUME IN VARIOUS AGE GROUPS 
Mean MCV varied significantly with age. When ANOVA test was 
conducted   (F= 0.069; P < 0.05*) the MCV was highest in the age group   
5-8 years (62.25 fl) and lowest in the age group of 1-4 years(60.75 fl). 
            Table-13: Mean corpuscular volume in various age groups 
Age  
(in 
years) 
MCV 
(fl) 
Mean 
S.D Study population
1 – 4 60.75 9.93 12 
5 – 8 62.25 9.5 16 
9 – 12 61.19 13.28 16 
Total 61.46 10.9 44 
 
MCH IN VARIOUS AGE GROUPS 
Mean MCH does not vary significantly with age. When ANOVA test was  
conducted (F= 0.250; P>0.05) the mean MCH was highest in the age group 
of 5-8 years (19.27pg) and lowest in the age group of  1-4 years (17.99 pg). 
       Table-14: Mean corpuscular haemoglobin in various age groups 
 
 
 
 
 
          Age 
(in years) 
MCH (pg) 
Mean S.D 
Study 
population 
          1-4 17.99 5.18 12 
5-8 19.27 4.68 16 
9-12 18.61 4.57 16 
Total 18.68 4.69 44 
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MEAN CORPUSCULAR HAEMOGLOBIN CONCENTRATION IN 
VARIOUS AGE GROUPS 
Mean MCHC does not vary significantly based on age. When ANOVA test 
was conducted (F= 0.757; P >0.05) the mean MCHC was highest in the age 
group 9-12years (25.05g/dl) and lowest in the age group of 1-4 years 
(23.20g/dl). 
Table-15:  Mean corpuscular haemoglobin concentration in Various age 
groups 
 
 
 
 
 
 
 
RED CELL DISTRIBUTION WIDTH IN VARIOUS AGE GROUPS 
Mean RDW varied significantly based on age. When ANOVA test was  
conducted (F= 4.961; P<0.05*) the mean RDW was highest in the age group 
1-4 years (53.01fl ) and lowest in the age group of  9-12 years (44.15fl). 
           
Age 
(in years) 
MCHC (g/dl)
Mean S.D 
     Study 
population 
1-4 23.20 2.00 12 
5-8 23.78 4.95 16 
9-12 25.05 4.40 16 
Total 24.08 4.12 44 
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         Table-16: Red cell distribution width in various age groups 
Age 
(in years) 
RDW (fl)
Mean S.D 
Study 
population 
1-4  53.01 9.94 12 
5-8 50.68 8.14 16 
9-12 44.15 5.51 16 
Total 48.94 8.56 44 
 
 
SERUM IRON IN VARIOUS AGE GROUPS 
Mean S. Iron does not vary significantly with age. When ANOVA test was 
conducted (F= 0.217; P>0.05) the mean Iron was highest in the age group of 
1-4 years (66.40 gµ/dl) and lowest in the age group of 5-8 years (45.99µg/dl)      
                   Table-17: Serum Iron in various age groups 
 
Age 
 (in 
years) 
Serum Iron(µg /dL) 
Mean S.D 
Study 
population 
     1-4 66.40 96.57 12 
5-8 45.99 80.07 16 
9-12 52.61 70.98 16 
Total 53.96 80.30 44 
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TIBC IN VARIOUS AGE GROUPS 
Mean TIBC does not vary significantly based on age. When ANOVA test 
was conducted (F= 0.569; P>0.05) the mean TIBC was highest in the age 
group 5-8 years (402.53µg/dl) and lowest in the age group of 9-12 years 
(372.40 µg/dl).   Table-18: TIBC in various age groups 
Age           
(in years) 
TIBC (µg /dl)
Mean S.D 
Study 
population 
1-4  380.18 109.17 12 
5-8 402.53 68.33 16 
9-12 372.20 73.17 16 
Total 385.40 82.01 44 
 
FERRITIN IN VARIOUS AGE GROUPS 
Mean ferritin does not vary significantly based on age. When ANOVA test 
was conducted (F= 0.928; P>0.05) the mean ferritin was highest in the age 
group of 1-4 years (195.15ng/dl) and lowest in the age group of 5-8 years 
(43.30ng/dl).      Table-19: Ferritin in various age groups 
    Age       
(in years) 
Ferritin (ng 
/dl) 
Mean 
S.D Study population 
1-4 195.15 533.78 12 
5-8 43.30 83.58 16 
9-12 104.26 134.00 16 
Total 106.88 292.01 44 
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GENDERWISE STATISTICAL ANALYSIS 
Mean Haemoglobin level does not vary significantly between boys and girls. 
When t-test was applied (t= 0.087; P>0.05) the average haemoglobin in boys 
was 6.77g/dl & for girls 6.71g/dl. 
Table-20:  Distribution of Haemoglobin in both sexes 
 
Gender  
Haemoglobin 
(g/dl) 
Mean 
S.D Study population 
Girls 6.71 2.32 25 
Boys  6.77 2.35 19 
Total 6.74 2.31 44 
 
DISTRIBUTION OF RBC COUNT IN BOTH SEXES 
Mean RBC counts do not vary significantly between boys and girls. When  
t- test was applied (t=1.707; P>0.05) the average RBC count in girls was 
3.40 million/mm3 where as for boys it was 2.81 million/mm3 
              Table-21: Distribution of RBC count in both sexes 
Gender 
 
RBC count 
(million/mm3)
Mean 
S.D Study population 
Girls 3.40 1.38 25 
Boys 2.81 0.68 19 
Total 3.15 1.16 44 
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DISTRIBUTION OF HAEMATOCRIT IN BOTH SEXES 
Mean Haematocrit does not vary significantly between boys and girls. When 
t- test was applied (t= 0.559; P>0.05) the average HCT in girls was 19.63% 
where as for boys it was 18.47%. 
Table-22: Distribution of Haematocrit in both sexes 
 
Gender 
HCT 
(%) 
Mean 
S.D Study population
Girls 19.63 7.58 25 
Boys 18.47 5.64 19 
Total 19.13 6.76 44 
 
DISTRIBUTION OF MCV IN BOTH SEXES 
MCV does not vary significantly between boys and girls. When  
t- test was applied (t=1.985; P>0.05) the average MCV in boys was 65.07fl 
where as for girls it was 58.71fl. 
Table-23: Distribution of MCV in both sexes 
 
Gender 
MCV 
(fl) 
Mean 
S.D Study population
Girls  58.71 11.75 25 
Boys  65.07 8.68 19 
Total 61.46 10.90 44 
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DISTRIBUTION OF MCH IN BOTH SEXES 
Mean MCH does not vary significantly between boys and girls. When  
t- test was applied (t= 0.256; P>0.05) the average MCH in girls was  
18.52pg where as for boys it was 18.89 pg. 
Table-24: Distribution of MCH in both sexes 
Gender  
 
MCH 
(pg) 
Mean 
S.D Study population
Girls 18.52 4.77 25 
Boys  18.89 4.71 19 
Total 18.68 4.69 44 
 
DISTRIBUTION OF MCHC IN BOTH SEXES 
Mean MCHC does not vary significantly between boys and girls. When  
t- test was applied (t=0.556; P>0.05) the average MCHC in girls was 
24.39g/dL where as for boys it was 23.68 g/dl. 
Table-25: Distribution of MCHC in both sexes 
 
Gender  
MCHC 
(g/dl) 
Mean 
S.D Study population 
Girls 24.39 4.08 25 
Boys  23.68 4.24 19 
Total 24.08 4.12 44 
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DISTRIBUTION OF RDW IN BOTH SEXES 
Mean RDW does not vary significantly between girls and boys. When  
t- test was applied (t=1.067; P>0.05) the average RDW in girls was 47.74fl 
where as for boys it was 50.52 fl. 
Table-26: Distribution of RDW in both sexes 
Gender RDW (fl)Mean S.D 
Study 
population 
Girls  47.74 9.03 25 
Boys  50.52 7.84 19 
Total 48.94 8.56 44 
 
DISTRIBUTION OF SERUM IRON IN BOTH SEXES 
Mean serum Iron does not vary significantly between boys and girls. When 
t- test was applied (t=1.575; P>0.05) the average serum Iron in girls was 
70.31µg/dl where as for boys it was 32.46 µg/dl. 
Table-27: Distribution of Serum Iron in both sexes 
Gender 
 
Serum Iron 
(µg/dl) 
Mean 
S.D Study population 
Girls 70.31 98.31 25 
Boys  32.46 40.69 19 
Total 53.96 80.30 44 
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DISTRIBUTION OF TIBC IN BOTH SEXES  
Mean TIBC does not vary significantly between boys and girls. When 
t- test was  applied ( F=1.079; P>0.05) the average serum Iron  in girls was 
373.79 µg/dl where as for boys it was 400.68 µg/dl. 
Table-28: Distribution of TIBC in both sexes 
Gender 
 
TIBC 
(µg/dl) 
Mean 
S.D   Study population 
Girls  373.79 90.81 25 
Boys  400.68 68.12 19 
Total 385.40 82.01 44 
 
DISTRIBUTION OF FERRITIN IN BOTH SEXES 
Mean ferritin does not vary significantly between boys and girls. When  
t- test was applied (t=0.796; P>0.05) the average ferritin  in girls was 141.87 
ng/dl where as for boys it was 70.81 ng/dl. 
Table-29: Distribution of ferritin in both sexes 
Gender 
 
Ferritin 
(ng/dl) 
Mean 
S.D Study population 
   Girls  141.87 370.69 25 
   Boys  70.81 131.43 19 
Total 111.19 291.88 44 
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STATISTICAL ANALYSIS BETWEEN β –TT AND MILD 
TO MODERATE (8-11.5 G/DL) IDA  
Mean haemoglobin varied significantly between IDA, β-TT. When t-test 
was applied (t=3.239; P<0.01) the mean Haemoglobin in IDA patients was 
8.99g/dl where as for β-TT 10.57g/dl. 
Table-30: Distribution of Haemoglobin in IDA & β-TT 
Anaemia  Haemoglobin(g/dL)Mean S.D 
Mild to 
moderate 
anaemia 
IDA 8.99 .81 11 
Β- TT 10.57 .23 3 
  Total 9.33 .98 14 
 
DISTRIBUTION OF MCV IN IDA & β-TT 
Mean MCV varied significantly between IDA, β-TT. When t-test was 
applied (t=5.402; P<0.01**) the mean MCV in IDA patients was 68.45 (fl) 
where as for β-TT 38.91(fl).           (**- significant at 1% level) 
Table-31: Distribution of MCV in IDA & β-TT 
Anaemia MCV (fl) Mean S.D 
Mild to 
moderate 
anaemia  
   IDA 68.45 9.20 11 
  β- TT 38.91 .16 3 
Total 62.12 14.95 14 
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DISTRIBUTION OF MCH IN IDA & β-TT 
Mean MCH do not vary significantly between IDA, β-TT. When t-test was 
applied (t=1.938; P>0.05) the mean MCH in IDA patients was 20.79 pg 
where as for β-TT 17.04 pg. 
Table-32: Distribution of MCH in IDA & β-TT 
Anaemia 
 
MCH (pg) 
Mean S.D 
Mild to 
moderate 
anaemia 
 IDA 20.79 3.24 11 
 Β- TT  17.04 .80 3 
Total 19.99 3.27 14 
 
DISTRIBUTION OF MCHC IN IDA & β-TT 
Mean MCHC do not vary significantly between IDA, β-TT. When t-test was 
applied (t=1.382; P>0.05) the mean MCHC in IDA patients was 23.83g/dl 
where as for β-TT 27.52 g/dl. 
Table-33: Distribution of MCHC in IDA & β-TT 
Anaemia 
 
MCHC (g/dl) 
Mean S.D 
Mild to 
moderate 
anaemia 
  IDA 23.83 4.49 11 
 Β- TT 27.52 .54 3 
Total 24.62 4.25 14 
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DISTRIBUTION OF RDW IN IDA & β-TT 
Mean RDW varied significantly between IDA, β-TT. When t-test was 
applied (t=5.407; P<0.01) the mean RDW in IDA patients was 47.77 fl 
where as for β-TT 35.02 fl.  
Table-34: Distribution of RDW in IDA & β-TT 
Anaemia RDW (fl) Mean S.D 
Mild to 
moderate 
anaemia 
    IDA 47.77 3.66 11 
   Β-TT 35.02 3.42 3 
Total 45.04 6.45 14 
 
DISTRIBUTION OF SERUM IRON IN IDA & β-TT 
Mean serum Iron does not vary significantly between IDA, β-TT. When  
t-test was applied (t=1.248; P> 0.05 ) the mean serum Iron  in IDA patients  
were 50.11 µg/dl whereas for  β-TT 131.03 µg/dl.  
Table-35: Distribution of S.Iron in  IDA & β-TT 
 
Anaemia 
Serum Iron 
(µg/dl) 
Mean 
S.D 
Mild to 
moderate 
anaemia 
   IDA 50.11 92.19 11 
   β-TT 131.03 130.36 3 
Total 67.45 101.68 14 
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DISTRIBUTION OF TIBC IN IDA & β-TT 
Mean TIBC varied significantly between IDA, β-TT. When t-test was 
applied (t=3.115; P<0.01) the mean TIBC in IDA patients were 424.87µg/dl 
whereas for β-TT 322.42 µg/dl. 
Table-36: Distribution of TIBC in IDA & β-TT 
Anaemia TIBC(µg/dl)Mean S.D 
Mild to 
moderate 
anaemia 
IDA 424.87 52.65 11 
β-TT 322.42 37.97 3 
Total 402.92 65.25 14 
 
DISTRIBUTION OF SERUM FERRITIN IN IDA & β-TT 
Mean serum ferritin varied significantly between IDA, β-TT. When t-test 
was applied (t= 22.800; P<0.01) the mean serum ferritin in IDA patients 
were 12.51 ng/dl whereas for β-TT 206.63 ng/dl  
Table-37: Distribution of Serum Ferritin in IDA & β-TT 
Anaemia Ferritin (ng/dl) Mean S.D 
Mild to 
moderate 
anaemia 
IDA 12.51 8.01 11 
Β-TT 206.63 26.54 3 
Total 54.11 83.61 14 
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DISCUSSION 
 
The current study mainly focused on the utility of serum iron profile, 
hemoglobin electrophoresis and peripheral smear in microcytic hypochromic 
anaemia. This study also attempted to elucidate the diagnostic accuracy of 
seven indices to discriminate mild to moderate Iron deficiency from 
 β - Thalassemia.  
 
AGE, SEX INCIDENCE & SEVERITY OF ANAEMIA:  
 
     The present study included patients between the age group of 1- 12 years. 
Two thirds of anaemic children were between the age of 5 & 12 years. This 
could be attributed to the increasing nutritional demands of growth spurt and 
puberty compounded by less attention to nutrition, amidst demanding academic 
pressures. 
       In the present study, girls with microcytic hypochromic anaemia out number 
the boys. This female preponderance could be due to less care of the girl child 
in Indian settings. Distribution of Hb, RBC, HCT, MCV, MCH, MCHC, RDW 
do not vary significantly in both sexes. 
           Mild anaemia (Hb10- 12 g /dl) was present in 26 cases (11.4%), 
moderate anaemia (Hb 8 -9.9g/dl) in 13 cases (29.5%) and severe anaemia (Hb 
<8 g/dl) in 5 cases (59.1%).    
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PREVALENCE OF IDA:   
      A study conducted by Mohemmed et al. in the 2006 & Looker et al. (37) in 
1997,  found that IDA is most prevalent in children.  
       This finding correlates with the present study where 72.73% of microcytic 
hypocromic anaemia was found to be due to Iron deficiency.  
[β-Thalassemia trait; 6.82%, β-Thalassemia major; 6.882% & anaemia of 
chronic disease; 13.64%].  
      This is an expected observation as early childhood represents a period of 
rapid growth and depletion of blood iron. (Looker et al.37). On the other hand, 
adolescent girls are also more susceptible to iron deficiency because of poor 
dietary intake in conjunction with high iron requirements related to rapid 
growth and menstrual blood loss. This study reflects similar findings probably 
due to the same factors.  
 
VALUE OF RED CELL INDICES IN DIFFERENTIATING 
BETWEEN ΒETA-TT & IDA: 
             Mean haemoglobin varied significantly between IDA, β-TT. The mean 
Hemoglobin in IDA patient was 8.99g/dL whereas for β-TT 10.57g/dL. Mean 
MCV varied significantly between IDA, β-TT, mean MCV in IDA patient was 
68.45 (fl) whereas for β-TT 38.91 (fl). 
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             MCV is known to be significantly low in β-Thalassemia as compared to 
Iron deficiency anaemia. Mean MCH does not vary significantly between IDA, 
β-TT,  mean MCH in IDA patient  was 20.79 pg whereas for  β-TT 17.04 pg. 
Mean MCHC does not vary significantly between IDA, β-TT, mean MCHC in 
IDA patient  was 23.83g/dl whereas for  β-TT 27.52 g/dl. 
 
 
 
RED CELL INDICES AND ITS USES: 
 
         A study conducted by M.A.Ehani et al.38 included 284 patients aged  
(range 10 – 38 years), this study utilized 4 indices including England and Fraser 
Index , Mentzer Index, Srivastava index & RBC count to discriminate 130 cases 
of IDA & 154 cases of b TT. Youden's index provides an appropriate measure 
of validity of a particular technique or question by taking into account both 
sensitivity and specificity 33,34, and was first used by Demir et al.38  Youdens 
index was calculated, showed MI (90.1) to be superior to Srivastava index 
(74.2) and England & fraser index(68.7) in that order. 
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Table-38: Following table shows sensitivity, specificity & Youden’s 
index calculated by Ehani et al.38 
Indices Sensitivity (%) Specificity (%) Youden’s index 
England &Fraser Index 
 
IDA 
 
B –TT 
 
 
 
99.2 
 
69.5 
 
 
69.5 
 
99.2 
 
 
 
68.7 
Mentzer Index 
 
IDA 
 
B-TT 
 
 
 
94.6 
 
95.5 
 
 
95.5 
 
94.6 
 
 
90.1 
Srivastava index 
 
IDA 
 
B-TT 
 
 
 
88.5 
 
85.7 
 
 
85.7 
 
88.5 
 
 
74.2 
RBC count 
 
IDA 
 
B= TT 
 
 
 
86.2 
 
98.1 
 
 
98.1 
 
86.2 
 
 
84.3 
 
 
 
According to another study conducted by Damier et al.38 sample size included 
was 63, best two indices were RBC count & RDWI. Youden’s index calculated 
was 82 & 80 respectively. 
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A study conducted by Ntaios et al.40 (2007), sample size included were 493, it 
was concluded that best two indices was Green and King, England and Fraser 
index, Youden’s index calculated was 70.9 , 63.2 respectively. 
 
A study conducted in the year 2007 by Beyan et al.41 included a sample size of 
111; it was concluded that best two indices were RBC count & Green and king 
indices, Youden’s index calculated was 73.7& 65.5 respectively. 
 
A study conducted in the year 2008 by Sirdah et al42 included a sample size of 
2196; it was concluded that best two indices were  Green and king indices, Red 
cell distribution width index, Youden’s index calculated was 68.6 & 68.4 
respectively. 
 
Another study conducted by Urrechaga et al (2008)43, sample size included 
were 318, they come to a conclusion that best indices was Green and King, 
Youden’s index calculated was 80.9. 
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Table-39: Youden’s index in various studies: 
References Sample size Best  indices Youden’ index 
Damier et al. 
(2002) 63 
 
RBC count 
 
RDWI 
 
 
82 
 
80 
Ntaios et 
al.(2007) 493 
 
Green & king 
 
England & Fraser 
 
 
70.9 
 
63.2 
Beyan et al. 
(2007) 111 
 
RBC count 
 
Green & King 
 
 
73.7 
 
65.5 
Sirdah et 
al.(2008) 2196 
 
Green &King 
 
RDWI 
 
 
68.6 
 
68.4 
Urrechaga et al. 
(2008) 318 
 
Green & King 
 
 
80.9 
Ehani et al. 284 
 
Mentzer 
 
 
90.1 
 
 
The S&L index was first defined by Shine and Lal in 1977 and was reported to 
have a sensitivity of 100%, a specificity of 11.8%and an efficiency value of 
59.5% for differentiating between β-TT and IDA patients.  
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Yeo et al.44. found the S&L index and mean cell volume (MCV) to be 
applicable when applied to pregnant women in Singapore. 
 
 Lafferty et al.45found the S&L index, MI and MCV to be valuable in 
distinguishing IDA and β-TT minor cases; the RDW and the E&F indices were 
not useful. 
 
 In studies including schoolchildren in Jordan, MI, MCV ≤72 fl, and E&F and 
S&L indices correctly identified 91.6%, 82.4%, 81.3% and 62.6%, respectively, 
of microcytosis cases as having or not having the β-TT trait12.  
 
AlFadhli et al.46 found the E&F index to be the most discriminatory and the 
S&L index the least when comparing patients with IDA to those with β-TT or 
TT minor. 
 
 A study conducted by Okan et al.47 found the S&L and G&K indices to be 
best at differentiating IDA from β-TT patients, and the RDW index to be the 
worst. In particular, the S&L index had the highest Youden index value in 
discriminating β-TT cases from those with moderate-to-severe IDA and also 
from those with mild IDA. 
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Table-40: Following table shows sensitivity, specificity, positive predictive 
value, negative predictive value & Youden’s index calculated in Okans et al 
study 
Indices Sensitivity
(%) 
Specificity
(%) 
PPV (%) NPV 
(%) 
Youden’s 
index 
Red blood cell count 
IDA 
B TT 
 
75 
86 
 
86 
75 
 
84.2 
77.4 
 
77.4 
84.2 
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Red cell distribution 
width 
IDA 
b- TT 
 
98 
6 
 
6 
98 
 
51 
75 
 
75 
51 
 
4 
Mentzer index 
IDA 
B-TT 
 
78 
82 
 
82 
78 
 
81.2 
78.8 
 
78.8 
81.2 
 
60 
Shine and Lal index 
IDA 
b-TT 
 
100 
91 
 
91 
100 
 
91.7 
100 
 
100 
91.7 
 
91 
England & Fraser 
index 
IDA 
B –TT 
 
97 
78 
 
78 
97 
 
81.5 
96.2 
 
96.2 
81.5 
 
75 
Srivastava index 
IDA 
b- TT 
 
79 
74 
 
74 
79 
 
75.2 
77.8 
 
77.8 
75.2 
 
53 
Green & king index 
IDA 
b- TT 
 
96 
83 
 
83 
96 
 
84.9 
95.4 
 
95.4 
84.9 
 
79 
 
RDW index 
IDA 
b-TT 
 
78 
83 
 
83 
78 
 
82.1 
87.3 
 
87.3 
82.1 
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Ricerca index 
IDA 
B-TT 
 
14 
98 
 
98 
14 
 
87.5 
53.2 
 
53.2 
87.5 
 
12 
 
 
 
67
Table-41: Following table shows sensitivity, specificity, Positive predictive 
value, negative predictive value found in the present study: 
Indices Anaemia Sensitivity Specificity PPV NPV Y.I 
Mentzer index 
IDA 100.0 100.0 100.0 100.0 100.0
B-TT 100.0 100.0 100.0 100.0 
Shine and Lal Index 
IDA 9.1 100.0 100.0 23.1 9.1 
B-TT 100.0 9.1 23.1 100.0 
England Fraser 
Index 
IDA 100.0 100.0 100.0 100.0 100.0
B-TT 100.0 100.0 100.0 100.0 
Srivasthava index 
IDA 100.0 100.0 100.0 100.0     
100.0
 
B-TT 100.0 100.0 100.0 100.0 
Green & king index 
IDA 100.0 100.0 100.0 100.0 100.0
B-TT 100.0 100.0 100.0 100.0 
RBC Distribution 
width index 
IDA 100.0 33.3 84.6 100.0 33.3 
B-TT 33.3 100.0 100.0 84.6 
Ricerca index 
IDA 100.0 0.0 78.6 0.0 
0.0 
B-TT 0.0 100.0 0.0 78.6 
 
Compared to the previous study, present study showed 100% sensitivity, 
specificity in 4 indices. This could be due to the small sample size in the present 
study. 
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               The present study found that, to differentiate mild to moderate 
IDA ( Hb 8.5 – 11 g/dl) from β-TT Mentzer index, England and Fraser 
index, Srivastava index & Green and king index had highest specificity as 
well as Youden’s index.  However RBC distribution width index was found 
to have reasonable specificity and sensitivity when compared to Shine and 
lal index & Ricerca index.  
 
Table- 42: Hematological parameter 
Parameter 
Ehana et al. Present study 
IDA B-TT IDA b-TT 
 
        Hb (g/dl) 9.3(+/-)1.89 
11.24(+/-) 
1.37 8.99(+/-)0.81 
   10.57(+/-)    
0.23 
MCV (fl) 70.04(+/-)     7.94 
62.02 (+/-) 
4.57 
68.45(+/-) 
9.20 
38.91(+/-) 
0.16 
MCH (pg/cell) 21.30 (+/-) 3.52 
19.68 (+/-) 
1.53 
20.79(+/-) 
3.24 17.04(+/-) 0.8
MCHC (g/dl) 29.88(+/-)   2.86 
30.93(+/-) 
1.71 
23.83(+/-) 
4.49 
27.52(+/-) 
o.54 
 
A study conducted by Ehana et al.38 found that MCHC was low in Iron 
deficiency anaemia, whereas MCV, MCH were low in Thalassemia & MCHC 
was normal.  The present study showed similar results. 
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SUMMARY AND CONCLUSION 
 
 
• In the present study of 44 children with microcytic hypochromic 
anaemia 12 were in 1-4 year age group (27.3%), 16 were in 5-8 year 
age group (36.4%) & 16 were in 9-12year age group (36.4 %). 
 
• Out of 44 patients studied, 56.8% were girls, 43.2% were boys. 
 
• Mild anaemia was observed in 11.4% of children; moderate anaemia 
was observed in 29.5 % of children, severe anaemia was observed in 
59.1% of cases. 
 
• Out of 44 cases, IDA constituted 72.73%, β-Thalassemia trait 
constituted 6.82%, β-Thalassemia major constituted 6.882% & 
Anaemia of chronic disease constituted 13.64%. 
 
• Following median values were obtained: 
          For IDA- RBC count- 2.58million/mm3, Hemoglobin- 5.85g/dl,    
MCH- 19.2 pg, MCHC- 22.45g/dl, RDW- 50.4 fl, S.Iron- 22µg/dl, Serum 
Ferritin- 4.67ng/dl & TIBC- 411.35µg/dl. 
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• β Thalassemia trait: - 
           RBC count 5.36 million/mm3, MCV-62.1fl, MCH- 20.6 pg, 
MCHC-22.1g/dl, S.Iron-199.8µg/dl, Serum Ferritin-307.3ng/dl & TIBC- 
267.1µg/dl.    
     
• Mean haemoglobin, MCV, MCH, RDW were lower in boys. Mean 
RBC, MCHC, HCT were higher in girls. Mean Serum Iron & Ferritin 
were low and TIBC was high in girls. 
 
 
• Out of 44 cases, 14 with mild to moderate anaemia caused clinical 
confusion between Iron deficiency anaemia and β-Thalassemia trait. 
After doing Iron profiles and electrophoresis 11 were concluded as 
Iron deficiency anaemia, and 3 were concluded as β-Thalassemia trait. 
 
• In remaining 30 cases, 3 turned out to β-Thalassemia major and 6 
were found to be anaemia of chronic disease. 
 
• In 6 children with anaemia of chronic disease, 3 were suffering from 
pneumonia, other two were suffering from urinary tract infection and 
remaining one child was suffering from tuberculosis. 
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• MCV was found to be lower in β-Thalassemia Trait than in IDA, 
which could have a useful application in differentiating these two 
conditions. 
 
• 7 indices were used to differentiate mild to moderate Iron deficiency 
anaemia and β-Thalassemia trait. For differentiating these two entities, 
Youdens index showed that Mentzer index, England and Fraser index, 
Srivastava index & Green and King index were equally superior to  
RBC Distribution width index, Shine and lal index & Ricerca index in 
that order. 
 
• In microcytic hypochromic anaemia peripheral smear, red cell indices, 
Serum Iron profile including Serum Iron, TIBC, Serum Ferritin and 
Haemoglobin electrophoresis were found to be useful parameters in 
the precise assessment of anaemia and its type.  
 
• Hb Electrophoresis, Serum Iron profile & Red cell indices are 
complementary to each other in the precise diagnosis of 
microcytic hypochromic anaemia of varied etiology, which would 
enable comprehensive wholesome treatment. 
BIBLIOGRAPHY 
 
 
1. Wharton BA. Iron deficiency in children: detection and prevention.  
Br J Haematol 1999; 106: 270−80. 
2. Lukens JN. The thalassemias and related disorders: an overview. In: Lee 
GR, et al., editors. Wintrobe’s Clinical Hematology. 10th ed. Giza: Mass 
Publishing, 1999: 405-33. 
3. Adamsky K, Weizer O, Amariglio N, et al. Decreased hepcidin mRNA 
expression in thalassemic mice. British Journal of Haematology. 
2004;124(1):123–124. 
4. Breda L, Gardenghi S, Guy E, et al. Exploring the role of hepcidin, an 
antimicrobial and iron regulatory peptide, in increased iron absorption in  
β-thalassemia. Annals of the New York Academy of Sciences. 2005;1054: 
417–422. 
5. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in 
β-thalassemia is characterized by increased iron absorption mediated by 
down-regulation of hepcidin and up-regulation of ferroportin. 
Blood. 2007; 109(11):5027–5035. 
6. Kattamis A, Papassotiriou I, Palaiologou D, et al. The effects of 
erythropoetic activity and iron burden on hepcidin expression in patients 
with thalassemia major.B Haematologica. 2006; 91(6):809–812. 
7. Dunn LL, Rahamanto YS, Richardson DR. Iron uptake andmetabolism in 
the new millennium. Trends Cell Biol. 2007; 17(2):93–100. 
8. Fredriksson A, Schroder N, Eriksson P, Izquierdo I, Archer T. Maze 
learning and motor activity deficits in adult mice induced by iron exposure 
during a critical postnatal period. Brain Res Dev Brain Res. 
2000;119(1):65–74. 
9.  Pin˜ ero DJ, Li NQ, Connor JR, Beard JL. Variations in dietary. 
10. Lozoff B, Beard J, Connor J, Barbara F, Georgieff M, Schallert T. Long 
lasting neural and behavioural effect of iron deficiency in infancy. Nutr 
Rev. 2006;64(5 pt 2):S34–S41. 
11. Shafir T, Angulo-Barroso R, Jing Y, Angelilli ML, Jacobson SW, Lozoff 
B. Iron deficiency and infant motor development. EarlHum Dev. 
2008;84(7):479–485. 
12. Miho maeda, Yoshitaka Fukunaga, two children with thalassemia 
identified during screening for anaemia in junior High school: J Nippon 
med sch 2004 ; 71 (4). 
13. Stefan D Anker and Stephen von Haeling: anaemia in chronic heart 
failure. First edition, Unimed 2009, 27-31. 
14. Dacie and Lewis practical Haematology, edited by S Mitchell Lewis, 
Barbara J Bain and Imelda Bates, tenth edition,Churchill Livingstone 2006. 
15. Hoffman, R., Benz, E. J., Shattil, S. J. (1998). Hematology: Basic 
principles and practice. New York, NY: Churchill Livingston. P: 397-427. 
16. Tatala, S., Svanberg, U. and Mduma, B. (1998). Low dietary iron 
availability is a major cause of anemia. American Journal of Clinical 
Nutrition, 69: 171−178. 
17. Asobayire, F., Adou, P., Davidsson, L., Cook, J. and Hurrell, R. (2001). 
Prevalence of iron deficiency with and without concurrent anemia in 
population groups with high prevalences of malaria and other infections. 
American Journal of Clinical Nutrition, 74(6): 776−782. 
18. Abalkhail, B. and Shawky, S. (2002). Prevalence of daily breakfast intake, 
iron deficiency anaemia and awareness of being anaemic among Saudi 
school students. International Journal of Food Sciences and Nutrition, 
53(6): 519−28. 
19. Hashizume, M., Kunii, O., Sasaki, S., et al. (2003). Anemia and iron 
deficiency among schoolchildren in the Aral Sea region, Kazakhstan. 
Journal of Tropical Pediatric, 49 (3): 172−177. 
20. Hopkins, R.M., Gracey, M.S., Hobbs, R.P., Spargo, R.M., Yates, M. and 
Thompson, R.C. (1997) The prevalence of hookworm infection, iron 
deficiency and anemia in an aboriginal community in north-west Australia. 
Medical Journal of Australia, 167(10):  554-5. 
21. Widdowson, E.M. and Spray, C.M. Chemical development in utero, 
Archives of Disease in Childhood, 77(1):205-214. 
22. Saarinen, U.M., Siimes, M.A. and Dallman, P.R. Iron absorption in 
infants: high bioavailability of breast milk iron as indicated by the extrinsic 
tag method of iron absorption and by the concentration of serum ferritin. 
Journal of Pediatric, 91(1):36-39. 
23. Elk, G. V. Iron deficiency. 2nd ed.: American Academy of Pediatrics. 
USA. P: 213-220. 
24. Conrad, M.E. and Umbreit, J.N. (2000). Iron absorption and transport-an 
update. American Journal of Hematology, 64: 287-298. 
25. Hopkins, R.M., Gracey, M.S., Hobbs, R.P., Spargo, R.M., Yates, M. and 
Thompson, R.C. (1997). The prevalence of hookworm infection, iron 
deficiency and anemia in an aboriginal community in north-west Australia. 
Medical Journal of Australia, 167(10): 554-5. 
26. Derman, D.P., Bothwell, T.H., MacPhail, A.P., et al., Importance of 
ascorbic acid in the absorption of iron from infant foods. Scand Journal of 
Hematology, 25(3): 193-201. 
27. Charlton, R. W. and Bothwell, T. H. Iron absorption. Annual Review of 
Medicine, 34:55-68. 
28. Christopher, N. F. (2003). Iron deficiency anemia. Nemours Foundation 
Center 1995-2005. Retrieved from the World Wide 
Web:http://kidshealth.org/parent/misc/reviewers.html. 
29. Arosio, P., Yokota, M. and Drysdale, J. W. Characterization of serum 
ferritin in iron overload: possible identity to natural apoferritin. British 
Journal of Hematology, 36(2): 199-207. 
30. Fauci, Braunwald, Kasperet al. Harrison’s principles of internal medicine, 
17th edition, 2008, Mc Graw Hill. 
31. Etienne Joosten. Strategies for the lab diagnosis of some common causes 
of anaemia in elderly patients. Gerontology 2004; 50:49-56. 
32. http://www.doctorslounge.com/hematology/labs/iron.htm. 
33. Pekkanen J, Pearce N. Defining asthma in epidemiological studies. Eur 
Respir J 1999;14:951-7. 
34. Burney PG, Chinn S, Britton JR, Tattersfield AE, Papacosta AO. What 
symptoms predict the bronchial response to histamine? Evaluation in a 
community survey of the bronchial symptoms questionnaire of the 
International Union Against Tuberculosis and Lung Disease. Int J 
Epidemiol 1989;18:165−73. 
35. Galanello R, Melis MA, Ruggeri R, Addis M, Scalas MT, Maccioni L, 
Furbetta M, Angius A, Tuveri T, Cao A: Beta0 thalassemia trait in Sardinia. 
Hemoglobin  3:33-46. 
36. Vrettou C, Traeger-Synodinos J, Tzetis M, Malamis G, Kanavakis E: 
Rapid screening of multiple betaglobin gene mutations by real-time PCR 
on the LightCycler: application to carrier screening and prenatal diagnosis 
of thalassemia syndromes. Clin Chem 2003, 49:769-776. 
37. Looker, A.C., Dallman, P.R., Carroll, M.D., Bunter, E.W. and Johnson, 
C.L. (1997). Prevalence of iron deficiency in the United States. Journal of 
American Medical Association, 277. No.12: 973-976. 
38. M.A.Ehani et al.; a New index for discrimination between Iron deficiency 
anaemia &  b Thalassemia mino: results in 284 patients. Pakiston Journal 
of biological sciences. 12(5)473-475,2009. 
39. Demir, A.,N. Yarali, T.fisgin, F. Duru and A. Kara, 2002. Most reliable 
indices in differentiation between thalassemia trait and iron deficiency 
anemia. Peadiatr. Int., 44: 612- 616. 
40. Shine I, Lal S:A strategy to detect β- thalassaemia minor.Lancet;i:692-694. 
41. Ntaios G, Chatzinikolaou A, Saouli Z, et al: Discrimination indices as 
screening tests for β- thalassemic trait. Ann Hematol 2007; 86: 487 – 491. 
42. Beyan C, Kaptan K, Ifran A: Predictive value of discrimination indices in 
differential diagnosis of iron deficiency anemia and beta thalassemia trait. 
Eur J Haematol 2007; 78: 524 – 526. 
43. Sirdah M, Tarazi I, Al Najjar E, et al: Evaluation of the diagnostic 
reliability of different RBC indices and formulas in the differentiation of 
the β-thalassaemia minor from iron deficiency in Palestinian population. Int 
J Lab Hematol 2008; 30: 324 – 330. 
44. Urrechaga, E,. 2008. Discriminant value of % microcyti/% hypochromic 
ratio in the differential diagnosis of micocytic anaemia . Clin. Chem. Lab. 
Med., 46: 1752- 1758. 
45. Yeo GS, Tan KH, Liu TC: The role ofdiscriminant functions in screening 
for β-thalassemia traits during pregnancy. Singapore Med J 1995; 36: 615 – 
618. 
46. Lafferty JD, Crowther MA, Ali MA, et al: The evaluation of various 
mathematical RBC indices and their efficacy in discriminating between 
thalassemic and non-thalassemic microcytosis. Am J Clin Pathol 1996; 
106: 201 –205. 
47. AlFadhli SM, Al-Awadhi AM, AlKhaldi D: Validity assessment of nine 
discriminant functions used for the differentiation between iron deficiency 
anemia and thalassemia minor. J Trop Pediatr 2007; 53: 93 – 97. 
48. V Okan, A Cigiloglu, S Cifci et al. Iron deficiency anaemia and b -
thalassaemia differentiation. The Journal of International Medical Research 
2009; 37: 25 – 30. 
49. Thein SL: Dominant beta thalassaemia: molecular basis and 
pathophysiology. Br J Haematol 1992, 80:273-277. 
50. Viprakasit V, Gibbons RJ, Broughton BC, Tolmie JL, Brown D, Lunt P, 
Winter RM, Marinoni S, Stefanini M, Brueton L, Lehmann AR, Higgs DR: 
Mutations in the general transcription factor TFIIH result in beta- 
thalassemia in individuals with trichothiodystrophy. Hum Mol Genet 2001, 
10:2797-2802. 
51. Webthal [http://www.talassemia.it/sito_eng/THAL_intro_eng.html] 
52. Mentzer WC. Differentiation of Iron Dificiency from Thalassemia trait. 
Lancet; 1:882. 
53. Walter T. DeAndraca l; Chadud P, Peralas CG, Iron Dificiency anaemia, 
Paediatrics; 84, 7-17. 
54. Ehsani, M.,A. Darvish, A. Aslani and F. Seighali, 2005. A newfomula for 
differentiation of Iron deficiency anaemia and thalassemia trait. Turk.J. 
Hematol., 22: 268- 268. 
 
ANNEXURE I  
PROFORMA 
Name 
Age  
Sex 
Residential address 
Informant 
Reliability of Informant  
Education of Informant 
Occupation 
Consanguinity 
Family history 
Birth and developmental history 
Order of birth 
 Spacing of birth 
Clinical history 
 Fatigability 
 Irritability 
 Poor weight gain 
 Breathlessness on exertion 
 H/O Passing worms in stool / Vomitus   
 H/O Bleeding tendencies  
 H/O Bone tenderness 
 H/O Recurrent urinary tract infection  
 H/O Chronic leg ulcers 
 H/O Jaundice 
 H/O Pica 
 Chronic drug intake  
 Having gone to endemic area for malaria during previous eight  weeks  
Menstrual history 
          H/O menorrhagia   
Physical examination  
 Pallor/Jaundice 
 Koilonychia 
 Hepatomegaly/ Splenomegaly 
 Hepatosplenomegaly 
 Skin purpura/ petechia, 
 Tachypnea/ Dyspnea 
 Pedal edema 
 Raised JVP 
                                          ANNEXURE-2: METHODOLOGY 
 
Patient with aneamia based on clinical symptoms, Hemoglobin, MCHC Level 
Peripheral  Smear  
Dimorphic Picture (Excluded) Microcytic hypochromic Basophilic Stippling 
• S.Iron 
• Iron Binding 
Capacity  
Normal / 
• S.Iron  
• S.Iron Binding 
Capacity  
 
• S.Iron 
• S.Iron 
Binding 
Capacity  
Chest X-ray for 
dense bone  
Lead Poisoning  
Iron Deficiency aneamia  Aneamia of chronic decease   
HB Electrophoresis  
Normal Abnormal 
BM Iron, Sideroblast 
Thalassemia  
Sideroblastic aneamia  
METHOD 
1. Patients with anaemia based on the clinical signs and symptoms were 
selected. 
2. They were tested for haemoglobin level, Mean corpuscular 
haemoglobin value, Mean corpuscular haemoglobin Concentration, 
Mean corpuscular volume. 
3. Peripheral smears were examined. 
4. With the help of these profiles patients were classified as microcytic 
hypochromic anaemia and included in the study. 
5. Patients with macrocytic and dimorphic blood picture were excluded. 
6. Patients with hypochromic microcytic anaemia were analyzed for 
Serum Iron, Serum Iron binding capacity, Serum ferritin, transferrin 
saturation. 
7. If Serum Iron level, ferritin were decreased and Iron binding capacity 
increased, that condition was categorized as Iron deficiency anaemia. 
8. If Serum Iron, ferritin were increased, Iron binding capacity was 
decreased - it indicates increased iron stores. Haemoglobin 
electrophoresis was done to rule out/ confirm Thalassemia trait. 
9. If electrophoresis showed increased Hb A2 it indicated Thalassemia 
minor. If  it showed increased Hb F it indicated Thalassemia major 
10. If Serum Iron, Serum Iron binding capacity were decreased, Serum 
ferritin was increased it was categorized as anaemia of chronic 
disease. 
   11. If smear showed basophilic stippling, possibility of lead poisoning 
was considered and X ray for bone density was done.     
                                                      ANNEXURE-3 
 
MASTER CHART: 1 
 
Sl IP No Age 
S
e
x 
Hb 
(g/dl) 
MCV 
(fl) 
MCH 
(Pg) 
MCHC
(g/dl) 
RBC 
(µ/dl)
HCT
(%) RDW 
S.Ir
on(µ
g/dl)
 
TIBC 
(µg/dl) 
 
Ferriti
n 
(ng/dl) 
Transferrin 
saturation 
(%) 
Hb Electrophoresis 
Result Hb A Hb A2 
 
Hb F
 
1 40764-09 5 F 4.1 77.4 25.6 22 3.21 24.85 53.5 22 480 0.5 4.58    IDA 
2 44992-09 3 M 3.5 76 24.8 22.7 2.7 20.52 50.4 22 444.9 2.74 4.97    IDA 
3 48837-09 12 M 8.7 79.4 24.5 27.4 2.59 20.56 51.7 22 395.8 20.26 6.97    IDA 
4 56630-09 1 F 8.3 69.3 24 22.7 3.77 26.13 47.3 28.2 357.7 27.2 7.88    IDA 
5 56888-09 10 F 4.5 58.1 12.5 21.5 2.51 14.58 48.1 23 412.4 6.96 5.58    IDA 
6 56960-09 6 F 5.8 56.4 20.6 30.5 5.62 31.70 41.7 345 200.8 285.5 86.08 8.3 2.5 89.2 β-TT 
7 56963-09 7 F 8.1 70.1 19.1 27.2 3.21 22.50 41.7 44.4 350.7 200.8 12.66    CD 
8 64184-09 8 F 4.9 47.4 10.7 22.6 1.58 7.49 63 38.2 405.9 51.56 9.43    IDA 
9 64279-09 3 F 3.7 43.4 11.7 22.6 1.4 6.08 65 44.6 424.3 22.53 13.75    IDA 
10 67985-09 12 M 10.4 76 27.9 36.8 3.72 28.27 47.1 36 242 381.7 16.07 97 2.5 0.5 CD 
11 67991-09 5 M 8.4 80.4 22.3 27.7 2.98 23.96 53.3 22 430.5 21.5 5.59 IDA 
12 68124-09 6 F 5.8 56 21.6 21.3 2.15 12.04 45 22 393.8 1.45 5.59    IDA 
13 68973-09 5 F 9.7 58.7 24.2 14.2 3.03 17.79 42.5 22 394.8 4.54 6.2    IDA 
14 69240-09 5 F 5.5 77.9 26.4 34 2.08 16.20 51.3 22 470.5 0.5 4.59    IDA 
15 18455-10 9 F 10.69 39 17.51 27.5 5.79 22.58 37 275 338.9 187.9 81.14 91.4 6 2.6 β-TT 
16 18492-10 12 F 4.6 66 24.6 21.5 5.36 35.38 42.1 165. 267.1 307.3 62.04 16.4 2,5 81.1 β-TM 
17 18497-10 8 F 5.8 56.4 20.6 30.5 3.21 18.10 42.1 38.3 343.6 97.57 11.15 97.4 2.6  CD 
18 23744-10 9 F 10.3 39 17.49 18.07 5.89 22.97 31.07 21 349.37 5.54 6.01 92.1 5.9 2 β-TT 
19 23760-10 6 F 4.1 55.9 13 22.3 3.15 17.61 48.8 25.9 401.2 0.5 6.47    IDA 
20 23774-10 2 F 4 55.3 12.8 23.1 3.12 17.25 48.6 23 397.2 16.96 5.79    IDA 
21 23775-10 11 M 4.3 55.9 13 22.1 2.17 12.13 49.5 22 472.4 0.5 4.66    IDA 
22 23791-10 2 F 4.5 55.7 10.8 21.5 2.17 12.09 48.4 21.2 399.6 4.81 5.31    IDA 
23 23793-10 3 F 6.2 50.1 13.7 22.1 3.15 15.78 42.1 43 100 1855 71.59 97 2.5 0.5 CD 
24 23841-10 1 F 6.2 59.1 19.3 21.1 2.03 12.00 72.5 23 373.2 3.43 6.16    IDA 
25 31921-10 11 M 8.1 55.1 18.7 21.1 3.75 20.66 42.1 29.8 359.9 235.1 82.8 97.5 2 1.5 CD 
26 31979-10 2 M 4.7 62.1 13.2 22.1 3.73 23.16 41.7 199. 278.3 385.1 71.79 10.5 2.5 87 β-TM 
27 33824-10 2 F 10.4 78 21.5 25.5 3.99 31.12 47.5 328 558 6.79 58.78    IDA 
28 34721-10 2 M 5.9 60.5 23 28.5 2.57 15.55 67.3 22 427 1.45 5.59    IDA 
29 35734-10 10 M 9.3 73.1 20.9 28.5 3.99 29.17 43.1 23 470 0.5 5.72    IDA 
30 35941-10 11 M 4.9 65.2 13.2 21.2 2.12 13.82 47.1 21 401.3 16.74 5.31    IDA 
31 36791-10 12 M 8.4 55.1 17.7 21.3 3.15 17.36 46.1 20 424.3 15.7 4.8    IDA 
32 37921-10 5 M 4.6 65.2 13.2 21.2 2.12 13.82 50.4 23 480.3 0.92 4.71    IDA 
33 37979-10 3 F 5.9 61.5 21 23.5 3.17 19.50 53 20 410.3 3.41 5.38    IDA 
34 37999-10 5 M 9.7 55.7 13.7 20.2 2.12 11.81 49 20 398.1 12.47 5.59    IDA 
35 39731-10 7 M 9.8 63.1 21.7 20.2 3.14 19.81 53 23 399.7 11.47 3.72    IDA 
36 39941-10 9 F 10.71 38.73 16.11 25 5.99 23.20 37 97.1 279 237 82.8 12 87.5 0.5 β-TM 
37 40020-10 3 F 7.8 58 20.1 23 2.05 11.89 52.3 22 391.7 12.4 7.46    IDA 
38 40120-10 5 M 5.4 57 20.1 22.1 2.05 11.69 50.4 22 421.7 1.51 5.52    IDA 
39 40320-10 7 M 3.4 61.4 16.5 23.1 2.06 12.65 52.6 23 474.1 0.5 4.73 IDA 
40 40341-10 9 F 8.1 70.1 19.1 27.2 3.17 22.22 46 21 434.7 7.4 5.59    IDA 
41 41400-10 8 M 6.2 57 19.1 21.3 2.03 11.57 72.5 23 394.7 1.52 5.52    IDA 
42 41740-10 11 M 8.4 73 22.3 21.3 3.14 22.92 42.1 22.1 278 235 81.8 96 3.5 1.5 CD 
43 42751-10 12 F 8.1 70.1 19.1 27.2 4.25 29.79 46 22 410 9.74 5.59    IDA 
44 43761-10 10 M 4.6 65.2 13.2 21.2 3.31 21.58 50.4 21 420 0.75 4.51    IDA 
 
 
 IDA  –  Iron Deficiency Anaemia 
 
    β-TM  –   Beta Thalassemia Trait 
 
 CD  –  Anaemia of Chronic Disease 
 
  
                                                      ANNEXURE-4 
 
MASTER CHART: 2 
 
Sl. 
No. IP No 
Mentzer 
Index 
Shine and 
Lal Index 
England 
Fraser Index 
Srivasthava 
Index 
Green & king 
Index 
RBC Distribution 
width Index 
Ricerca 
Index Result 
1 48837-09 30.66 1544.57 29.91 9.46 374.64 1584.93 19.96 IDA 
2 56630-09 18.38 1152.60 20.63 6.37 273.68 869.47 12.55 IDA 
3 67991-09 26.98 1441.51 32.02 7.48 410.17 1438.03 17.89 IDA 
4 68973-09 19.37 833.86 3.77 7.99 150.97 823.35 14.03 IDA 
5 33824-10 19.55 1308.06 18.61 5.39 277.88 928.57 11.90 IDA 
6 35734-10 18.32 1116.81 19.21 5.24 247.64 789.63 10.80 IDA 
7 36791-10 17.49 537.37 6.55 5.62 166.62 806.38 14.63 IDA 
8 37999-10 26.27 425.04 1.68 6.46 156.72 1287.41 23.11 IDA 
9 39731-10 20.10 864.01 7.56 6.91 215.33 1065.06 16.88 IDA 
10 40341-10 22.11 938.58 23.03 6.03 279.07 1017.22 14.51 IDA 
11 42751-10 16.49 938.58 21.95 4.49 279.07 758.73 10.82 IDA 
12 18455-10 6.74 266.33 -23.64 3.02 52.64 249.22 6.39 β-TT 
13 23744-10 6.62 266.02 -21.79 2.97 45.88 205.73 5.28 β-TT 
14 39941-10 6.47 241.65 -24.21 2.69 51.82 239.23 6.18 β-TT 
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